Of note, the 5HT2AR antagonist ketanserin was found to modulate hemostasis, contrary to the 5HT2ARAb, which suggests that this antibody may be safer than some of the small molecule antagonists for this receptor. It is also to be noted that one cannot exclude contributions from non-platelet ...